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population-based cohort to inform health care planners on trends in costs and resource 
needs related to fractures. METHODS: We used the Population Health Research Data 
Repository for the Province of Manitoba, Canada which is a comprehensive collection 
of databases including physician visits, hospitalizations and pharmaceutical prescrip-
tions. Age and sex-adjusted fracture rates were calculated for men and women age 
ﬁfty years and older from 1986 to 2006 according to fracture site (deﬁned by ICD-9-
CM codes) and mechanism (presence/absence of ICD-9-CM external injury codes). 
Generalized linear models with generalized estimating equations were used to derive 
adjusted annual rates and test the linear change overall, and for men and women 
separately. RESULTS: Osteoporotic fractures (non-traumatic fractures of the hip, 
forearm, spine and humerus) showed a signiﬁcant linear decline (0.8% per-annum 
[95% CI 0.3–1.2%]), with a greater decline in women (1.0% [0.4–1.7%]) than in 
men (0.5% [0.0–1.3%], P  .05 for sex interaction). Similar trends were seen for all 
fractures sites: hip 0.9% (0.2–1.7%), forearm 0.8% (0.4–1.3%), humerus (0.7% 
[0.2–1.2%]) and spine (0.5% [0.0–1.0%]) A greater reduction in traumatic fractures 
was observed (1.8% per-annum [95% CI 1.0–2.6%]), with a greater decline in men 
(2.2% [1.3–3.1%]) than in women (1.3% [0.2–2.4%], P  .05 for sex interaction). 
Similar results were seen when testing the difference between the initial 5 years 
(1986–1991) and the ﬁnal ﬁve years (2001–2006) of data. CONCLUSIONS: We 
observed a decrease in both non-traumatic (osteoporotic) and traumatic fracture rates 
over the study period. This decline was apparent in years prior to widespread osteo-
porosis testing or availability of modern pharmacotherapy.
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OBJECTIVES: It has been reported that bone fracture the risk of developing increases 
for patients who had fractures once before, and and that such patients do not receive 
enough osteoporosis treatment. In this present study, we investigated incidence of 
recurrent fractures and the circumstances of pharmacotherapy for osteoporosis among 
patients who had experience ﬁrst hip fracture. METHODS: Female patients 65 years 
and older who had experienced ﬁrst hip fractures from January 1, 2006 to December 
31, 2007 were enrolled at 25 hospitals.We reviewed their medical records and con-
ducted a patient survey to collect information on surgical methods, osteoporosis 
treatments and prognosis for 1 year after ﬁrst hip fracture.The questionnaires were 
ﬁlled out by either the patient or family member. This interim analysis was conducted 
for 477 patients of 7 hospitals out of 2,266 enrolled patients. RESULTS: The average 
age was 84.0 (66–103) years old. In terms of fracture type, we identiﬁed 237 cervical 
cases and 237 intertrochantric fractures, with 3 cases that were not speciﬁed. A total 
of 94.3 % of the patients received an operation. During hospitalization, 26.2% were 
on pharmacotherapy and 22.9% received no pharmacotherapy. For the observational 
period, 1 year after ﬁrst fractures, 13.4% of the patients received pharmacotherapy, 
but 57.2% received no treatment. For the observational period, 44 patients (9.2%) 
experienced recurrent fractures and 18 (3.8%) out of those suffered hip fractures. 
CONCLUSIONS: In this study, the incidence of recurrent hip fractures among patients 
who have already experienced a ﬁrst hip fracture was 3,800/100,000 person-year. This 
is 7.4 times the rate found in the general population of the same age group. Despite 
this increase in incidence rate, only 13% of patients had received osteoporosis treat-
ment after the ﬁrst hip fracture. Japanese patients who have already suffered from a 
ﬁrst hip fracture must be considered high risk patients who should be treated with 
preventive action.
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OBJECTIVES: Osteoporosis is characterized by low bone mass and increased fracture 
risk. Increased mortality rates have been documented following fractures, particularly 
hip and vertebral. Our aim was to compare short-term and long-term mortality rates 
following an incident fracture in men and women at different sites (hip, wrist, spine, 
humerus and others). METHODS: We identiﬁed a population-based cohort of men 
and women with non-traumatic incident fractures between 1986 and 2006 within the 
hospital, physician and pharmacy administrative database repository of the Province 
of Manitoba, Canada. The cohort-entry date was the date of a ﬁrst fracture (index 
fracture) after age 50 years. Two matched controls from the same databases were 
identiﬁed for each case. Crude and adjusted mortality rates for each fracture site were 
computed separately for men and women. Secular trends in fracture site-speciﬁc mor-
tality rates over the study period were tested using generalized linear models. 
RESULTS: We identiﬁed 23,514 index fractures in men and 52,897 in women. The 
crude mortality rates were consistently higher in men compared to women. Highest 
ﬁrst year mortality rates were noted after hip (women 20.1% vs. men 33.6%) followed 
by spine fractures (13.9% vs. 15.8%), with lower mortality rates after humerus (7.4% 
vs. 15.3%), wrist (3.4% vs. 5.3%) and other fractures (9.2% vs. 11.0%). Similar 
rankings by fracture site were seen for year ﬁve mortality: hip fractures (women 53.1% 
vs. men 66.7%) followed by spine (38.4% vs. 43.1%), humerus (26.6% vs. 41.2%), 
wrist (15.7% vs. 21.2%) and other fractures (26.5% vs. 29.3%). Post-fracture mortal-
ity rates were generally stable over the study period. CONCLUSIONS: Fractures at 
all sites are associated with signiﬁcant mortality rates, particularly in men. Better 
understanding of factors associated with increased post-fracture mortality will inform 
the development of practice guidelines and improved clinical outcomes.
MUSCULAR-SKELETAL DISORDERS – Cost Studies
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Leartsakulpanitch J, Sakulbumrungsil R
Chulalongkorn University, Bangkok, Thailand
OBJECTIVES: To determine the ﬁnancial impact of inclusion of glucosamine in the 
hospital formulary of Petchabun Hospital. METHODS: Conventional NSAIDs, cele-
coxib, glucosamine were included in the analysis. Hospital perspective was used and 
we considered only patients who failed to control pain by acetaminophen. Treatment 
cost of GI and CV event was calculated based on decision tree model in which cooper-
ated with probability from the literature and local DRG cost data. Average cost of 
drug use per patient per year was calculated from the medical history and computer-
ized dispensing data. Delphi technique with all treating orthopaedics was used to 
obtain the estimates of number of patient eligible for glucosamine use and effect on 
volume of other drugs’ use in the following years. Probabilistic analysis was used to 
capture the certainties around estimations. We analyzed this data in a 5-year timeframe 
(2005–2009) as we assumed the steady penetration of glucosamine was reached. 
RESULTS: In 2005, we estimated there was an increase in drug budget for knee 
osteoarthritis treatment around 0.8 million baht (23,000 US$) which was growing 
from 2004 at 7%; it was similar to the growth rate in the ealier year. This was mainly 
due to the expected reduction in NSAIDs and coxib uses. The forecast budget impact 
in 2006–2009 were about 0.8, 0.6, 0.5, and 0.2 million baht at the growth rate 6.2%, 
4.4%, 3.5% , and 1.5%respectively. Cost of glucosamine was found to be the most 
sensitive variable, followed by cost of celecoxib and number of patients using glucos-
amine. CONCLUSIONS: Hospital administrators found that glucosamine use resulted 
in an affordable ﬁnancial burden to the drug budget for knee osteoarthritis in the 
hospital. However, to ensure the effective use of glucosamine, they developed the 
guideline for glucosamine use and also monitor the clinical and economic outcomes. 
Updated analyses were also recommended to obtain the reliable information for 
budget planning in the following years.
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OBJECTIVES: Gout is a chronic condition caused by hyperuricemia, a metabolism 
and excretion disorder characterized by intense pain “ﬂares” in affected joints. The 
objective was to estimate budgetary impact of adding febuxostat to a US health plan 
formulary for gout treatment. METHODS: An interactive model was developed using 
decision analysis methods comparing expected annual number of gout ﬂares and 
associated costs among members treated with febuxostat 40 mg/80 mg vs allopurinol 
300 mg for 1 year. Underlying model data and default inputs were obtained from 
clinical trials, retrospective studies, and published literature. Gout prevalence was 1%, 
among which 34% were estimated to be treated. Average febuxostat 1-year market 
share was assumed to be 3.9%. Model outputs included total per-member per-month 
(PMPM) cost; gout-, tophi-, and ﬂare-related medical costs and total pharmacy costs, 
and number needed to treat (NNT). Costs were adjusted to 2008 $US. User-modiﬁed 
sensitivity analysis on gout prevalence, ULT market share, and pharmacy cost was 
conducted. RESULTS: In a hypothetical 1-million-member health plan, adding febux-
ostat 40 mg/80 mg to the formulary is expected to increase total annual cost by $0.008 
PMPM, reduce gout-related costs by $26,010, and increase pharmacy costs by 
$124,494. Model data projected a reduction of 22 ﬂares when adding febuxostat to 
the formulary and NNT of 6.25 patients on febuxostat to prevent 1 gout ﬂare. Sensi-
tivity analyses indicate a positive relationship between febuxostat market share and 
gout ﬂares avoided and gout-related medical costs. CONCLUSIONS: This robust 
model evaluates the 1-year pharmacy and medical cost offsets on total payer budget. 
Adding a new ULT to a US health plan formulary minimally impacts total payer 
budget as shown by the marginal PMPM cost increase and signiﬁcant gout-related 
medical savings.
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OBJECTIVES: Two simulation models were developed to analyze the cost and out-          
comes of the biological agents currently marketed in Italy vs disease-modifying anti-
rheumatic drugs (DMARDs) that affect the progression of rheumatoid arthritis (RA). 
METHODS: A Markov model over 10 years was constructed with four disease states            
according to functional status (HAQ). Disease progression (transition probabilities 
between the states) was taken from clinical trial data and published literature. Patient 
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mortality depends on epidemiological evidence relating reduced risk to HAQ improve-
ment.. Costs and utilities associated with different HAQ levels were based on data 
from cohort studies and cross-sectional surveys in Italy. RESULTS: In the base case    
scenario (10% of patients treated in each disease state) we estimated that treatment 
with any biologic had an incremental cost of 26.4% over 10 years (including only            
direct costs). By analysing each disease state separately, costs vary from 22.3% to            
28.3%. The inclusion of potential avoided nursing home admissions and indirect          
costs/lost employment further improved the cost-effectiveness ratio. The model shows 
that a higher percentage of treated patients with a HAQ score between 1.1 and 2.6 
improves the cost-effectiveness ratio. The greater effectiveness of biological agents      
contribute to maintaine patients in less severe disease states by favoring disease 
improvement and remission; this signiﬁcant health beneﬁt is also reﬂected on mortality 
rate. Sensitivity analyses showed long-term HAQ progression with biologic therapies         
and discounting as most sensitive variables. CONCLUSIONS: Our results suggest that    
biologic therapies are cost-effective when compared with DMARDs. The model is 
further suitable for use in a wide range of other cost-effectiveness questions in rheu-
matoid arthritis. It appears to accurately capture disease progression and its effects 
and can therefore be useful for estimating cost-effectiveness of new treatments in RA 
in different Italian health care settings.
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OBJECTIVES: To evaluate the annual economic impact of biotherapies for the treat-
ment of RA patients. METHODS: Target population was deﬁned as adults belonging 
to RA medical Diagnosis Related Group (DRG) in the French national database of 
the Information System Program Management (PMSI) in hospital. The total direct 
costs considered were: treatment costs (current published prices, April 2009), hospi-
talization costs including administration cost in hospital (DRG, V11 March 2009), 
and for ambulatory patients the rheumatologist follow-up and subcutaneous injection 
costs. Treatment cost was calculated according to treatment dose, length and duration 
as reported in real life data. Real life data were based on a registry (AIR PR) and 
record from market analysis (A  A panel study March 2008). Biotherapies market 
share data were issued from the GFK Performance Tracker (Q3 2008). RESULTS: A 
total of 15,873 patients were identiﬁed in 2007 with biotherapies of Abatacept: 952 
(6), a19,618 (81), a18,676,336 (8); Adalimumab: 4762 (30),   a14,950 (patient injec-
tion) (99), a15,464 (nurse injection) (98), a71,252,500 (32); Etanercept: 5873 (37),   
a14,693 (patient injection) (99), a14,849 (nurse injection) (98), a86,575,567 (39); 
Inﬂiximab*: 2381 (15), a 12,144 (84), a28,914,864 (13); Rituximab**: 1905 (12),   
a 6,451 1 cycle (89) a12,789 2 cycles (90), a16,029,434 (7); Total: 15873 (100), NA,   
a221,448,701 (100) for Patients N (%), Annual costs / patient (% acquisition costs),          
Total annual costs (%).CONCLUSIONS: In real life setting annual RA treatment 
costs/patient in France varies from a6,451 to a19,618 depending on the biotherapy 
used. Drug acquisition cost represents the major part of the annual costs. The global 
annual cost is a221, 448, 701.
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BACKGROUND: Rheumatoid arthritis (RA) is a systemic autoimmune disease which 
affects about 0.5% of the population in developing countries. The current biologic 
DMARDs approved in Brazil as 1st line therapy are: inﬂiximab, etanercept, adalim-
umab (anti-TNF therapies), abatacept (T-cell co-stimulation therapy) or tocilizumab 
(IL-6 receptor antagonist). OBJECTIVES: To assess the budget impact of offering 
tocilizumab as an option to a pool of patients with rheumatoid arthritis (RA) in Brazil. 
METHODS: The perspective is private payer in Brazil. Only direct costs were consid-
ered which comprised of: drug, management and administrations costs [Scheinberg et 
al. 2005]. Drug costs were taken from public sources [Kairos magazine. May, 2009]. 
Base case dosages considered were: tocilizumab (8 mg/kg dosage each 4 weeks) and 
inﬂiximab {4.3 mg/kg (Ollendorf et al. 2005) at weeks 0, 2, 6 and every 8 weeks}, 
assuming a 70 kg patient, adalimumab (40 mg every other week), etanercept (50 mg 
every week) and abatacept (750 mg at weeks 0, 2, 4 and then every 4 weeks). The 
discount rate taken was 5% according to the Brazilian guidelines for Health Technol-
ogy Assessment (HTA) [Vianna et al. 2007] since a 5-year horizon was taken for this 
analysis. Both the treatment mix forecast and the tocilizumab penetration change were 
projected based on market research data. The results are expressed in 2009 Brazilian 
Reais (US$1 y $Brz2.5). RESULTS: Total annual costs were $Brz81,021 for tocili-
zumab, $Brz92,789 for etanercept, $Brz98,541 for adalimumab, $Brz105,283 for 
inﬂiximab and $Brz 85,020 for abatacept. Based on the change in the forecast;, a total 
savings for a period of 5 years were $Brz1,573,902 for each 100 treated patients, 
when comparing the group of patients received tocilizumab to the group of patients 
that did not receive tocilizumab. CONCLUSIONS: Findings suggest tocilizumab offers 
potential costs reductions in the private health care system in Brazil.
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OBJECTIVES: The aim of the analysis was to assess the impact on the Polish health 
care budget the ﬁnancing of Arava® within ambulatory reimbursement list compared 
to Arava® ﬁnancing within the National Health Fund rheumatoid arthritis therapeutic 
program; all costs were calculated from public payer’s perspective in Poland in a one-
year time horizon. METHODS: Direct medical costs regarding drug costs, diagnostic 
costs, ambulatory and hospital treatment valid from a public payer’s perspective were 
taken into account in the analysis. Ofﬁcial retail price of Arava® was obtained from 
Sanoﬁ-Aventis from Poland. Five reimbursement scenarios were taken into consider-
ation depending on reimbursement limits and levels of coverage by public payer. 
RESULTS: Introduction of Arava® on ambulatory reimbursement list results in incre-
mental savings between 4.4 million PLN and 6.4 million PLN (depending on reim-
bursement scenario) comparing to continuation of Arava® treatment within the 
rheumatoid arthritis therapeutic program from public payer’s perspective. Financing 
Arava® within reimbursement list could increase number of patients treated with a 
Arava® from around 4.3 thousands to 5,3 thousands (at present 3 thousands of 
patients are treated with leﬂunomide within therapeutic program) or extend duration 
of treatment with additional from 5 up to 9 months. CONCLUSIONS: Financing 
Arava® within ambulatory reimbursement list generates substantial savings for the 
public payer in Poland compared to ﬁnancing within a therapeutic program and pro-
vides treatment with Arava® for a greater number of patients with rheumatoid arthritis 
or extends the duration of treatment.
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OBJECTIVES: To describe the disease management and the cost of patients presenting 
a diagnosis of sciatica in the hospital perspective. METHODS: We performed a local 
data base request from the medical information system (PMSI) of the University Hos-
pital of Montpellier. We considered three consecutive years (2006, 2007, 2008) which 
allowed us to get a follow-up and a traceability of patients over this period. We ana-
lyzed a group of patients 18–50 years old admitted across acute care, day care or 
mid-term care sectors with the following diagnosis codes M 54, M 5415, M 5416 and 
M 5417 of the ICD-10. RESULTS: A total of 232 patients were selected over the 
period representing a total of 541 admissions (i.e. 2.3 admissions per patient). The 
mean o SD age was 39 o 8 years female represent 45% of the patients. We observed 
175 admissions in acute care (“less than 24 h” admissions excluded) with a mean 
length of stay of 7 o 5.2 days. Day-care represents 15.4% of admission in acute care 
sector. We observed 38 admissions in mid-term care with a mean length of stay of 3 
o 4.8 days. Few patients (3 %) were admitted consecutively in acute care and in mid 
term care thereafter. Surgery was the reason of ﬁrst admission for six patients. The 
cost is estimated at a2055 per patient admitted in an acute care sector. CONCLU-
SIONS: In our sample, we noted a high rate of admission per patient for diagnosis, 
medical treatment or physical therapy reasons as the main pattern of sciatica manage-
ment in-hospital. Admissions for surgery were marginal. Our ﬁgures are key informa-
tion to specify management of sciatica and transition probabilities in decision tree 
models. Thus, we would simulate the impact of innovative medical device on the 
burden of disease and disclose where are the most prominent societal beneﬁts.
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BACKGROUND: Rheumatoid arthritis (RA) is a systemic autoimmune disease which 
affects 0.5% of the population in developing countries. The current biologic DMARDs 
approved in Brazil as 1st line therapy are: inﬂiximab, adalimumab, etanercept, (anti-
TNF therapies) and abatacept (T-cell co-stimulation therapy) or tocilizumab (IL-6 
receptor antagonist). OBJECTIVES: To assess the budget impact of offering tocili-
zumab as an option to a pool of patients with RA in Brazil. METHODS: The perspec-
tive was from a public payer. Only direct costs were considered which comprised: 
drug, management and administrations costs [Scheinberg et al. 2005]. Base case 
dosages considered were: tocilizumab (8 mg/kg dosage each 4 weeks) and inﬂiximab 
[4.3 mg/kg (Ollendorf et al. 2005) at weeks 0, 2, 6 and every 8 weeks], assuming a 
70 kg patient, adalimumab (40 mg every other week), etanercept (50 mg every week) 
and abatacept (750 mg at weeks 0, 2, 4 and then every 4 weeks). We took the 
maximum price to government as a basis to all therapies [Jun, 2009]. The discount 
rate taken was 5% according to the Brazilian guidelines for (HTA) [Vianna et al. 
2007] and a 5-year horizon was assumed. Both the treatment mix forecast and the 
tocilizumab penetration change were projected based on market research data. The 
results are expressed in 2009 Brazilian Reais (US$ 1 y $Brz2.5). RESULTS: Total 
annual costs were $Brz47,566 for tocilizumab, $Brz50,785 for etanercept, $Brz53,909 
for adalimumab, $Brz58.603 for inﬂiximab and $Brz50,048 for abatacept. Based on 
the change in the mix of treatment forecast, a total savings for a period of 5 years 
